ロード中...
Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess in vitro aggregation in patients with atrial...
保存先:
| 出版年: | Clin Appl Thromb Hemost |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7573709/ https://ncbi.nlm.nih.gov/pubmed/33054412 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620948585 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|